Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markku S Nieminen

Showing results (1-10 of 253) with videos related to

Pageof 26
Sort By:
International Journal of Cardiology|September 21, 2015
Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysisSimona Silvetti, Markku S Nieminen
The American Journal of Cardiology|September 27, 2005
Definition and epidemiology of acute heart failure syndromesMarkku S Nieminen, Veli-Pekka Harjola
European Journal of Heart Failure|March 12, 2008
Heart failure in the elderly: how risky is it to be discharged?Markku S Nieminen, Veli-Pekka Harjola
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|November 26, 2003
Considerations on the efficacy and safety of levosimendan in ischemic heart failureMarkku S Nieminen, Esa-Pekka Sandell
Annals of Medicine|March 10, 2020
Poor adherence to beta-blockers is associated with increased long-term mortality even beyond the first year after an acute coronary syndrome eventJaakko Allonen, Markku S Nieminen, Juha Sinisalo
International Journal of Cardiology|July 27, 2013
Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed?Piero Pollesello, Zoltán Papp, Markku S Nieminen
European Journal of Epidemiology|September 17, 2003
Clinical findings, outcome and treatment in patients > or = 75 years with acute myocardial infarctionMervi Kotamäki, Timo E Strandberg, Markku S Nieminen
European Heart Journal Supplements : Journal of the European Society of Cardiology|December 19, 2017
The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failureMarkku S Nieminen, Cândida Fonseca, Dulce Brito, et al.
Journal of Cardiovascular Pharmacology|March 12, 2009
Effects of levosimendan on the energy balance: preclinical and clinical evidenceMarkku S Nieminen, Piero Pollesello, Gusztáv Vajda, et al.
Scandinavian Cardiovascular Journal : SCJ|May 25, 2002
Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart diseaseJuha Sinisalo, Frej Fyhrquist, Martti Syrjälä, et al.
Pageof 26

Showing results (1-10 of 253) with videos related to

Sort By:
Pageof 26
International Journal of Cardiology|September 21, 2015
Repeated or intermittent levosimendan treatment in advanced heart failure: An updated meta-analysisSimona Silvetti, Markku S Nieminen
The American Journal of Cardiology|September 27, 2005
Definition and epidemiology of acute heart failure syndromesMarkku S Nieminen, Veli-Pekka Harjola
European Journal of Heart Failure|March 12, 2008
Heart failure in the elderly: how risky is it to be discharged?Markku S Nieminen, Veli-Pekka Harjola
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|November 26, 2003
Considerations on the efficacy and safety of levosimendan in ischemic heart failureMarkku S Nieminen, Esa-Pekka Sandell
Annals of Medicine|March 10, 2020
Poor adherence to beta-blockers is associated with increased long-term mortality even beyond the first year after an acute coronary syndrome eventJaakko Allonen, Markku S Nieminen, Juha Sinisalo
International Journal of Cardiology|July 27, 2013
Lessons from Lisbon on AHF drug treatment: is it really true that all-old-failed-all-new-will-succeed?Piero Pollesello, Zoltán Papp, Markku S Nieminen
European Journal of Epidemiology|September 17, 2003
Clinical findings, outcome and treatment in patients > or = 75 years with acute myocardial infarctionMervi Kotamäki, Timo E Strandberg, Markku S Nieminen
European Heart Journal Supplements : Journal of the European Society of Cardiology|December 19, 2017
The potential of the inodilator levosimendan in maintaining quality of life in advanced heart failureMarkku S Nieminen, Cândida Fonseca, Dulce Brito, et al.
Journal of Cardiovascular Pharmacology|March 12, 2009
Effects of levosimendan on the energy balance: preclinical and clinical evidenceMarkku S Nieminen, Piero Pollesello, Gusztáv Vajda, et al.
Scandinavian Cardiovascular Journal : SCJ|May 25, 2002
Stimulated release of endothelin-converting enzyme is simultaneous with tissue-type plasminogen activator and decrease in coronary heart diseaseJuha Sinisalo, Frej Fyhrquist, Martti Syrjälä, et al.
Pageof 26